Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Healthtrust
Federal Trade Commission
Chubb
Covington
Dow
Chinese Patent Office
US Department of Justice
Cipla

Generated: September 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MIGLITOL

« Back to Dashboard

Clinical Trials for miglitol

Trial ID Title Status Sponsor Phase Summary
NCT00032487 Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) Completed National Eye Institute (NEI) Phase 3 This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
NCT00032487 Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) Completed SmithKline Beecham Phase 3 This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
NCT00032487 Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) Completed VA Office of Research and Development Phase 3 This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
NCT00213070 Double-Blind Trial of Miglitol in Type 2 Diabetic Patients With Insulin Treatment Completed Sanwa Kagaku Kenkyusho Co., Ltd. Phase 3 The purpose of this study is evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus with treated insulin.
NCT00213109 Open Trial of Miglitol in Type 1 Diabetic Patients With Insulin Treatment Completed Sanwa Kagaku Kenkyusho Co., Ltd. Phase 3 The purpose of this study is evaluate the clinical efficacy and safety of Miglitol in patients with Type1 Diabetes Mellitus treated with insulin.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for miglitol

Condition Name

Condition Name for miglitol
Intervention Trials
Type 2 Diabetes Mellitus 7
Diabetes Mellitus, Type 2 2
Type 1 Diabetes Mellitus 1
Pharmacokinetics of ASP1941 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for miglitol
Intervention Trials
Diabetes Mellitus 10
Diabetes Mellitus, Type 2 9
Pancreatitis 1
Pancreatic Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for miglitol

Trials by Country

Trials by Country for miglitol
Location Trials
United States 15
Japan 7
Canada 3
Puerto Rico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for miglitol
Location Trials
California 1
Arizona 1
Washington 1
Virginia 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for miglitol

Clinical Trial Phase

Clinical Trial Phase for miglitol
Clinical Trial Phase Trials
Phase 3 7
Phase 1 1
N/A 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for miglitol
Clinical Trial Phase Trials
Completed 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for miglitol

Sponsor Name

Sponsor Name for miglitol
Sponsor Trials
Sanwa Kagaku Kenkyusho Co., Ltd. 6
Drug Safety and Effectiveness Network, Canada 3
Canadian Institutes of Health Research (CIHR) 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for miglitol
Sponsor Trials
Other 9
Industry 8
NIH 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Cipla
Colorcon
Harvard Business School
Healthtrust
US Army
Cerilliant
Johnson and Johnson
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.